Adeno-associated virus (AAV) is rapidly becoming the go-to biological delivery method for the latest gene therapy breakthroughs; more than 1,300 unique gene therapy products are currently under development and nearly half are reliant on AAV. Thus, the ability to scale production of these impactful therapies is critical to bringing down costs and accelerating the process from research to commercialization.
Watch this webinar to learn about:
- The broad range of products and technologies available in the gene therapy field
- Flexible solutions for clinical and commercial scale viral vector production
- Process diversity and scale-up challenges in upstream processes
